68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis

NCT02560376 · Unknown status

Last updated 2026-05-28

This clinical trial is testing a new imaging method called 68Ga-NOTA-exendin-4 PET/CT to help locate insulinomas and diagnose nesidioblastosis in adults with these conditions.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Early Phase 1 First exploratory testing in people.

Type Interventional (clinical trial)

Design open-label (no blinding) diagnostic study

Participants 100 people Planned (estimated).

Who can join Ages 6–70 · all sexes

Timeline Started 2014-02 · est. completion 2016-12

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT02560376 ↗

Description as written by the study sponsor.

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-exendin-4 in insulinoma and nesidioblastosis patients. A single dose of 55.5-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.

Treatments tested

68Ga-NOTA-exendin-4 also known as 68Ga-NOTA-MAL-cys40-exendin-4 Drug

68Ga-NOTA-exendin-4 were injected into the patients before the PET/CT scans

Main thing measured	Standardized uptake value of 68Ga-NOTA-exendin-4 PET/CT in Diagnosis of Insulinoma and Nesidioblastosis
Sponsor	Peking Union Medical College Hospital
Conditions studied	Insulinoma, Nesidioblastosis
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02560376 ↗